Absci Corp is a biotechnology company that focuses on developing cutting-edge technologies to accelerate the discovery and development of new biotherapeutics, including antibodies, proteins, and vaccines. The company was founded in 2011 by Sean McClain and is headquartered in Vancouver, Washington, USA.
Absci's platform combines synthetic biology, data science, and robotics to enable high-throughput screening of millions of protein variants, significantly speeding up the drug discovery process. Their technology allows for the rapid identification and optimization of potential therapeutic candidates, reducing the time and cost traditionally associated with drug development.
The company's Integrated Drug Creation Platform (IDCP) is a cloud-based platform that integrates all aspects of the drug discovery process, from protein design and synthesis to high-throughput screening and lead optimization. This platform has been adopted by pharmaceutical companies and research institutions to advance their drug development pipelines. As such, Absci's approach has gained significant attention in the biotech industry, leading to several strategic partnerships and collaborations with major pharmaceutical companies.